June 16, 2020 / 11:09 AM / a month ago

BRIEF-Neurocrine Biosciences, Takeda Announce Collaboration To Develop Potential Therapies For Psychiatric Disorders

June 16 (Reuters) - Takeda Pharmaceutical Co Ltd:

* NEUROCRINE BIOSCIENCES AND TAKEDA ANNOUNCE COLLABORATION TO DEVELOP AND COMMERCIALIZE POTENTIAL THERAPIES FOR PSYCHIATRIC DISORDERS

* NEUROCRINE BIOSCIENCES - COLLABORATION INCLUDES 3 CLINICAL-STAGE ASSETS WITH MOST ADVANCED MOLECULE IN PHASE II FOR NEGATIVE SYMPTOMS OF SCHIZOPHRENIA

* NEUROCRINE BIOSCIENCES - TAKEDA WILL RECEIVE $120 MILLION IN UPFRONT CASH

* NEUROCRINE BIOSCIENCES- TAKEDA WILL BE ENTITLED TO DEVELOPMENT MILESTONES OF UP TO $495 MILLION

* NEUROCRINE BIOSCIENCES- TAKEDA WILL BE ENTITLED TO COMMERCIAL MILESTONES OF UP TO $1.4 BILLION

* NEUROCRINE BIOSCIENCES- TAKEDA WILL BE ENTITLED TO UP TO DOUBLE-DIGIT ROYALTIES ON NET SALES

* NEUROCRINE BIOSCIENCES- TAKEDA RETAINS ABILITY TO OPT IN OR OUT OF 50:50 PROFIT SHARE ON ALL CLINICAL PROGRAMS AT CERTAIN DEVELOPMENT EVENTS

* NEUROCRINE- AGREEMENT GIVES CO EXCLUSIVE WORLDWIDE RIGHTS TO EARLY-TO-MID-STAGE PSYCHIATRY PIPELINE COMPOUNDS WITHIN TAKEDA’S NEUROSCIENCE PORTFOLIO Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below